Therapeutic area
Oncology
Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.govMethods & limitations
Approvals since 2023
69
Originals, plus breakthrough or accelerated new uses
Recruiting Phase 2
1,445
Industry-sponsored
Recruiting Phase 3
598
Industry-sponsored
Recruiting Phase 4 (post-approval)
34
Industry-sponsored
Recent approvals
- Pimjetmi (Pimicotinib) · Emd Serono NovelNov 10, 2026
To treat adults with symptomatic tenosynovial giant cell tumors in whom surgical resection may cause worsening functional limitation or severe morbidity
- Lyrfigtu (Lirafugratinib Hydrochloride) · Elevar NovelPriority reviewOrphanSep 23, 2026
To adults with previously treated unresectable, locally advanced or metastatic cholangiocarcinoma harboring a fibroblast growth factor receptor 2 gene fusion or other rearrangement
- Pixclara (Floretyrosine F-18) · Telix NovelPriority reviewOrphanSep 11, 2026
To use with positron emission tomography to differentiate recurrent or progressive glioma from treatment-related change in conjunction with other diagnostic evaluations
- Etcamah (Camizestrant) · Astrazeneca NovelSep 4, 2026
To treat hormone receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer upon detection of ESR1 mutation during aromatase inhibitor and CDK4/6 inhibitor therapy
- Rasonque (Daraxonrasib) · Revolution Medicines NovelPriority reviewOrphanAug 26, 2026
To treat metastatic pancreatic cancer
- Jideytro (Zidesamtinib) · Nuvalent NovelOrphanJul 22, 2026
To treat adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer after receiving a ROS1 kinase inhibitor
- Revtorpyk (Gedatolisib) · Celcuity NovelPriority reviewJul 14, 2026
In combination with fulvestran, to treat hormone receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer without a PIK3CA mutation detected following progression on or after treatment with at least one line of endocrine therapy in the metastatic setting
- Ibrance (Palbociclib) · Pfizer Breakthrough therapyJun 24, 2026
- Ibrance (Palbociclib) · Pfizer Breakthrough therapyJun 24, 2026
- Cavhanza (Nilotinib) · Cycle OrphanMay 29, 2026
- Decnupaz (Pivekimab Sunirine-Pvzy) · Abbvie INC NovelPriority reviewOrphanMay 27, 2026
To treat adults with blastic plasmacytoid dendritic cell neoplasm
- Beqalzi (Sonrotoclax) · Beone Medicines USA NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanMay 13, 2026
To treat adults with relapsed or refractory mantle cell lymphoma after at least two lines of systemic therapy, including a Bruton's tyrosine kinase inhibitor
- Bizengri (Zenocutuzumab-Zbco) · Merus N.V. Breakthrough therapyPriority reviewOrphanMay 8, 2026
- Jakafi Xr (Ruxolitinib Phosphate) · Incyte Corp OrphanMay 1, 2026
- Veppanu (Vepdegestrant) · Rigel Pharms NovelMay 1, 2026
To treat estrogen receptor-positive, human epidermal growth factor receptor 2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy
Recruiting trials by phase
Industry-sponsored drug and biologic trials.
Most approvals since then, by company
Drugs in development
Investigational drugs in Phase 2 and 3 trials for conditions in this area, most trials first.
- SKB264MK-2870, Sacituzumab TirumotecanPhase 353 trials
Merck & Co. · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Cervical Cancer
- BMS-986507BL-B01D1, Iza-brenPhase 351 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- AdebrelimabSHR-8068, HRS -4642Phase 341 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Advanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumors
- CadonilimabAK104Phase 331 trials
Akeso · Hepatocellular Carcinoma, Gastric / Gastroesophageal Junction Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
- SHR-A1811Trastuzumab RezetecanPhase 327 trials
Jiangsu HengRui Medicine Co., Ltd. · Advanced Colorectal Cancer, Recurrent or Metastatic Cervical Cancer, Ovarian Cancer
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- SerplulimabHLX10, HLX43Phase 325 trials
Shanghai Henlius Biotech · Non Small Cell Lung Cancer, Carcinoma, Hepatocellular, SCLC, Extensive Stage
- SintilimabIBI308Phase 321 trials
Innovent Biologics (Suzhou) Co. Ltd. · Hepatocellular Carcinoma, Solid Tumor, HCC - Hepatocellular Carcinoma
- AdabelimumabSHR-A2102, SHR2554Phase 320 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Advanced Solid Tumors, Prostate Cancer, Advanced Urothelial Carcinoma
- BL-M07D1Phase 317 trials
Sichuan Baili Pharmaceutical Co., Ltd. · HER2-positive Breast Cancer, Non-squamous Non-small Cell Lung Cancer, Her2-positive/Low-expression Urinary and Digestive Tract Tumors
- I-DXdDS-7300a, MK-2400Phase 317 trials
Merck & Co. · Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Esophageal Squamous Cell Carcinoma
- GiredestrantRO7197597, GDC-9545Phase 316 trials
Roche (Genentech) · Early Breast Cancer, Breast Cancer, Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
- HS-20093Ris-Rez, Risvutatug rezetecanPhase 316 trials
Hansoh BioMedical R&D Company · Neoplasms, Lung, Sarcoma, Osteosarcoma
- Telisotuzumab AdizutecanABBV-400Phase 316 trials
AbbVie · c-MET, Non-Squamous Non-Small Cell Lung Cancer, Metastatic Colorectal Cancer
Largest recruiting Phase 3 trials
- Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy FemalesPivotal-lookingRecruiting
Shanghai Bovax Biotechnology Co., Ltd.Industry
NCT04422366 · 8,000 participants (planned) · Start Apr 28, 2020 · Primary completion Sep 15, 2027
Drug: 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha); GARDASIL® · For: Cervical Cancer; Vulvar Cancer; Vaginal Cancer and 11 more
Sites: Liuzhou, China
- A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With Intermediate or High Risk Early Breast CancerPivotal-lookingRecruiting
Shandong Suncadia Medicine Co., Ltd.Industry
NCT07349069 · 5,500 participants (planned) · Start Mar 4, 2026 · Primary completion Dec 2030
Drug: HRS-8080 Tablets; Letrozole tablets and 3 more · For: Breast Cancer
Sites: Nanjing, China; Shanghai, China
- A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine TherapyPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT05774951 · 4,300 participants (planned) · Start Mar 31, 2023 · Primary completion Apr 20, 2027
Drug: Camizestrant; Tamoxifen and 3 more · For: Breast Cancer, Early Breast Cancer
Sites: Birmingham, Alabama; Dothan, Alabama; Anchorage, Alaska · 709 sites in all
- Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT03486873 · 3,500 participants (planned) · Start Aug 21, 2018 · Primary completion Aug 4, 2043
Drug: Pembrolizumab; Standard of Care (SOC) and 5 more · For: Solid Tumors; Hematologic Malignancies
Sites: Tucson, Arizona; Bakersfield, California; Fresno, California · 782 sites in all
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06966700 · 2,400 participants (planned) · Start Jun 30, 2025 · Primary completion Mar 23, 2033
Drug: Sacituzumab tirumotecan; Pembrolizumab and 8 more · For: Breast Neoplasms; Triple Negative Breast Neoplasms; HR Low-Positive/HER2-Negative Breast Neoplasms
Sites: Gilbert, Arizona; Phoenix, Arizona; Tucson, Arizona · 338 sites in all
- Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive SubjectsPivotal-lookingRecruiting
Greenwich LifeSciences, Inc.Industry
NCT05232916 · 2,250 participants (planned) · Start Dec 16, 2022 · Primary completion Dec 2031
Drug: Placebo; GLSI-100 · For: Breast Cancer
Sites: Mobile, Alabama; Goodyear, Arizona; Tucson, Arizona · 179 sites in all
- Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2Pivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07431281 · 2,130 participants (planned) · Start Feb 3, 2026 · Primary completion Aug 16, 2029
Drug: Sonesitatug vedotin; Rilvegostomig and 6 more · For: Gastric Cancer; Gastroesophageal Junction Adenocarcinoma; Esophageal Cancer
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 314 sites in all
- A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast CancerPivotal-lookingRecruiting
Shanghai JMT-Bio Inc.Industry
NCT07441460 · 1,800 participants (planned) · Start Mar 6, 2026 · Primary completion Aug 7, 2034
Drug: KN026; HB1801 and 7 more · For: Resectable HER2-positive Breast Cancer
Sites: Shanghai, China
- A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian CancerPivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07213804 · 1,630 participants (planned) · Start Oct 22, 2025 · Primary completion Nov 2028
Drug: Sofetabart Mipitecan; Paclitaxel and 6 more · For: Ovarian Neoplasms; Fallopian Tube Neoplasms; Peritoneal Neoplasms and 1 more
Sites: Birmingham, Alabama; Phoenix, Arizona; Burbank, California · 264 sites in all
- Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic CancersPivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07493304 · 1,600 participants (planned) · Start Aug 26, 2026 · Primary completion Jul 18, 2031
Drug: REGN7508; Apixaban · For: Venous Thromboembolism (VTE)
Sites: Hialeah, Florida; New York, New York; El Paso, Texas · 14 sites in all
More: Oncology news · literature
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.